|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01652 FUSEN PHARM
Nominal 
0.920 +0.010 (+1.099%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 565,608 | 15.018% | 491,757 | 385,664 | 486,854 | 407,388 |
| Cost of Sales | (266,102) | -0.238% | (266,736) | (174,531) | (220,787) | (194,900) |
| Gross Profit | 299,506 | 33.101% | 225,021 | 211,133 | 266,067 | 212,488 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (20,329) | -46.512% | (38,007) | (19,280) | (22,637) | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (20,292) | -3.459% | (21,019) | (1,969) | 24,252 | 4,535 | |
| Profit / (Loss) before Taxation | (29,448) | -4.985% | (30,993) | 23,791 | 78,405 | 63,814 | |
| Taxation | (6,847) | 87.025% | (3,661) | (7,178) | (15,737) | (11,555) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 18 | -63.265% | 49 | 32 | 7,463 | 1,175 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (36,277) | 4.832% | (34,605) | 16,645 | 70,131 | 53,434 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 8,843 | -43.765% | 15,725 | 7,097 | 7,730 | 6,869 |
| Depreciation & Amortisation | 35,798 | 4.792% | 34,161 | 23,785 | 22,457 | 21,232 |
| Directors' Emoluments | 5,769 | 123.605% | 2,580 | 2,655 | 2,259 | 1,200 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -5.000 | 0.000% | -5.000 | 2.000 | 9.000 | 7.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.910 | 0.910 | 0.670 |
| Dividend Payout Ratio (%) | -- | -- | -- | 45.500% | 10.111% | 9.571% |
| Cash flow per share ($) | (0.098) | -- | 0.146 | 0.062 | 0.195 | 0.025 |
| NBV per share ($) | 0.751 | -- | 0.810 | 0.855 | 0.852 | 0.842 |
| Remarks: | Real time quote last updated: 28/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -36,941,000 |
| %Change | -- |
| EPS / (LPS) | RMB -0.050 |
| NBV Per Share (¥) | RMB 0.694 |